Innovent Biologics, the Hong Kong-listed company based in Suzhou, China, signs a global licensing and collaboration agreement with Pfizer to develop oncology medicines. The deal covers 12 cancer treatment programs, with Innovent and Pfizer jointly working on research and development. Under the agreement, Pfizer makes an upfront payment of US$650 million to Innovent. The companies also outline total potential payments of up to US$10.5 billion, with the remainder available through development, regulatory, and commercial milestone payments, according to Innovent’s exchange filing and the announcements from the companies. CNBC reports that Innovent’s shares rise by as much as 10% after the announcement. Other coverage and the joint press release describe the arrangement as a strategic collaboration aimed at accelerating the development of innovative oncology medicines. The reports do not add further program-level details beyond the number of oncology initiatives and the overall payment structure.
Innovent Biologics and Pfizer sign up to $10.5 billion deal for 12 oncology programs
Innovent Biologics, the Hong Kong-listed company based in Suzhou, China, signs a global licensing and collaboration agreement with Pfizer to develop oncology medicines. The deal covers 12 cancer treat...
- Innovent Biologics and Pfizer enter a global licensing and collaboration agreement for oncology medicines.
- The agreement covers development of 12 cancer treatment programs.
- Pfizer pays Innovent a US$650 million upfront amount.
- Total payments are up to US$10.5 billion, including milestone payments tied to development, regulatory, and commercial outcomes.
- Innovent’s share price rises sharply—up to about 10%—following the announcement.
China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which is based in Suzhou in China’s eastern Jiangsu...
2 months agoInnovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
2 months agoSAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12...
2 months ago
Brazil sues Discord for nearly $97 million over alleged child-safety failures
Brazil files a lawsuit against Discord in federal court, seeking about 500 million reais (around $97 million) in damages...
Godfrey Lebeya to testify at South Africa’s Madlanga Commission
Former Hawks boss Lt-Gen Godfrey Lebeya is expected to testify at the Madlanga Commission on Thursday. The available re...
EFCC Chair Says Commission Forfeited Over $500m to Nigeria in Three Years
The chair of Nigeria’s Economic and Financial Crimes Commission (EFCC), Ola Olukoyede, says the agency has forfeited “ov...